scholarly article | Q13442814 |
P50 | author | Luc Hittinger | Q21055496 |
P2093 | author name string | Jean-Pascal Lefaucheur | |
Stéphane Moutereau | |||
Sylvain Loric | |||
Thibaud Damy | |||
Aziz Guellich | |||
Violaine Plante-Bordeneuve | |||
Dania Mohty | |||
Jean-François Deux | |||
Soulef Guendouz | |||
Stéphane Rappeneau | |||
P2860 | cites work | Universal definition of myocardial infarction | Q34007701 |
Biomarkers of cardiovascular disease: molecular basis and practical considerations | Q34526561 | ||
Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. | Q35002777 | ||
Tissue Doppler imaging in the evaluation of left ventricular diastolic function | Q35865679 | ||
Transthyretin-related familial amyloidotic polyneuropathy | Q36189972 | ||
Amyloidosis and the heart: a comprehensive review | Q36603755 | ||
Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes | Q36846286 | ||
Recommendations for the evaluation of left ventricular diastolic function by echocardiography | Q37383745 | ||
Echocardiographic evaluation of systolic and diastolic function in patients with cardiac amyloidosis | Q37909598 | ||
Diagnosis of amyloidosis by abdominal fat aspiration. Analysis of four years' experience | Q38172331 | ||
The systemic amyloidoses | Q41596634 | ||
Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins | Q44022591 | ||
Diagnostic efficiency of troponin T measurements in acute myocardial infarction | Q46657809 | ||
Cardiac troponin T at 96 hours after acute myocardial infarction correlates with infarct size and cardiac function | Q47310426 | ||
Impact of longitudinal myocardial deformation on the prognosis of chronic heart failure patients | Q48270711 | ||
Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis | Q48323509 | ||
Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: new evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosis | Q48404782 | ||
Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis | Q48496969 | ||
The value of BNP testing | Q48527750 | ||
Is elevated plasma B-natriuretic peptide in amyloidosis simply a function of the presence of heart failure? | Q48765394 | ||
Comparison of four right ventricular systolic echocardiographic parameters to predict adverse outcomes in chronic heart failure. | Q51799502 | ||
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardio | Q57217547 | ||
Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis? | Q57259435 | ||
Outcome of exerciseelectrocardiographyin familial amyloidotic polyneuropathy patients, Portuguese type, under evaluation for liver transplantation | Q57259455 | ||
P433 | issue | 4 | |
P304 | page(s) | 212-220 | |
P577 | publication date | 2013-08-21 | |
P1433 | published in | Amyloid | Q4749545 |
P1476 | title | Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis | |
P478 | volume | 20 |
Q33168881 | Cardiac amyloidosis: pathogenesis, clinical context, diagnosis and management options |
Q35244195 | Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis |
Q36559736 | Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy |
Q26776496 | Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis |
Q92486932 | Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy? |
Q92826292 | Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease |
Q40532663 | Identification of prognostic markers in transthyretin and AL cardiac amyloidosis |
Q58104657 | Imaging cardiac innervation in hereditary transthyretin (ATTRm) amyloidosis: A marker for neuropathy or cardiomyopathy in case of heart failure? |
Q36338381 | Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS). |
Q38547033 | Improving strategies for the diagnosis of cardiac amyloidosis |
Q58029886 | Molecular imaging of misfolded protein pathology for early clues to involvement of the heart |
Q58125154 | Noninvasive detection of cardiac involvement in patients with hereditary transthyretin associated amyloidosis using cardiac magnetic resonance imaging: a prospective study |
Q59295474 | Patient-Specific Biomechanical Modeling of Cardiac Amyloidosis – A Case Study |
Q41149554 | Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness |
Q37009096 | Prevalence, Severity, and Prognostic Value of Sleep Apnea Syndromes in Cardiac Amyloidosis |
Q57653734 | Senile transthyretin cardiac amyloidosis in patients with plasma cell dyscrasias: importance of cardiac biopsy for making the correct diagnosis |
Q95729110 | Value of natriuretic peptides and tissue Doppler imaging in the estimation of left ventricular filling pressure in patients with cardiac amyloidosis |
Q55425790 | Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: clinical presentation, diagnosis, management and emerging therapies. |